French 4D bioprinting company Poietis has announced the commercialization of its Next Generation Bioprinting (NGB) systems. The bioprinting platform, which has been in development for the past four years, is designed for tissue engineering applications in research and development or for clinical batch production.
In recognizing the varying needs of R&D and clinical bioprinting applications, Poietis is offering two systems based on the same core NGB technology: the NGB-R for research in biology and tissue engineering, and the NGB-C for clinical use. The NGB-C is designed for the eventual production of Advanced Therapy Medicinal Products (ATMP) and to meet the bioprinting needs of Poietis’ partners. Notably, the NGB-C enables clinicians to bioprint in a closed system, with completely aseptic conditions to ensure standardization of printed tissues.
The NGB-R, for its part, is built specifically for research purposes and therefore offers flexibility in terms of what print technology is used and what materials are printed. The NGB-R system also integrates an embedded cellular imaging system for real-time monitoring and includes a complete software suite for the management of bioprinting protocols.
Still, both systems do share many features, including automation and robotics technologies, advanced online sensors such as cell microscopy, and AI processing. In terms of bioprinting hardware, the NGB platform integrates laser, extrusion and inkjet by micro-valve printing, covering most bioprinting techniques in a single platform.
By basing both the R&D and clinical machines on the same NGB technology, Poietis also aims to make the transition from research to clinical testing as seamless as possible. The ultimate goal is for the NGB platform to accelerate the development of and access to bioprinting therapies for patients.
In terms of applications, Poietis has targeted three main markets since its founding in 2014: in vitro tissue models (to replace animal testing in dermo-cosmetics), pharmaceutical research and regenerative medicine. With the launch of its new NGB platform, the company is aiming to establish a new standard for bioprinting and tissue manufacturing.
“We have upgraded the NGB platform to an automated robotic system to improve the standardization of manufacturing processes and the functionality of biological tissues,” said Fabien Guillemot, President and CSO of Poietis. “The combination of multimodal bioprinting with the acquisition and the online processing of printed cell images at cellular resolution will also ensure that what we design is what we print.”
Poietis has had something of a big year. In January, it launched Poieskin, the first bioprinted skin model for the commercial market. Just a couple of months later, the France-based company reported that it had raised €5 million through a Series A financing round. This funding is being dedicated to accelerating development towards the first implantation of a bioprinted tissue. Most recently, the company announced a partnership with pharmaceutical company Servier to develop and produce bioprinted liver tissue.
“In parallel with our first applicative developments on bioprinted tissues for in vitro models, we continue to evolve our business model to meet the expectations of tissue engineering specialists and biology researchers,” added Bruno Brisson, Co-Founder and Business Development Director of Poietis, about the bioprinter launch. “The commercialization of NGB-R bioprinters will provide new opportunities for tissue engineering researchers at the preclinical stage, while the NGB-C system will support clinical developments that will be carried out initially in the framework of partnerships benefiting from the same manufacturing platform.”